{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016366","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.754173+00:00","generated_at":"2026-05-17T05:16:42.492566+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"bioAffinity closes $4.8M public offering; Nasdaq compliance extension received","bullets":["Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.","After closing and warrant exercises, common shares outstanding total 3,100,402.","1-for-30 reverse stock split effective Sept 19; eliminated ~$4M in derivative liabilities.","Company believes it regained compliance with Nasdaq minimum bid price and equity requirements; extension granted to Oct 2.","Warrant amendments and exercises contributed ~$2.8M equity and ~$1.3M cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016366","json":"https://secwatch.observer/filing/0001493152-25-016366.json","markdown":"https://secwatch.observer/filing/0001493152-25-016366.md","text":"https://secwatch.observer/filing/0001493152-25-016366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225016366/0001493152-25-016366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225016366/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:16:42.492566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}